GlassScriptPhysician profile
Kerrin D Burte
NPI 1336144567
$15,692.41
in general payments reported to CMS, 2019-2025
44 companies · $1,985 in 2025
The $1,985 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,808 · 2020: $1,534 · 2021: $2,171 · 2022: $2,473 · 2023: $2,431 · 2024: $2,292 · 2025: $1,985.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,439 · Education: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,438.99 |
| Education | $268.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,245.76 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $2,179.12 | 2019-2024 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $1,864.86 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $1,769.25 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Novartis Pharmaceuticals Corporation | $843.92 | 2019-2025 | |
| Pfizer INC. | $783.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $734.84 | 2021-2025 | Saphnelo |
| Lilly USA, LLC | $543.31 | 2019-2025 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $508.61 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $443.37 | 2019-2023 | |
| Glaxosmithkline, LLC. | $351.04 | 2019-2025 | Benlysta, Nucala |
| Aurinia Pharma U.S., INC. | $318.75 | 2022-2025 | Lupkynis |
| Radius Health, INC. | $290.12 | 2019-2025 | Tymlos |
| Genentech USA, INC. | $281.16 | 2019-2024 | Actemra |
| Mallinckrodt Hospital Products INC. | $180.33 | 2020-2022 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kerrin Burte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.